Earnings call transcript: Agilent Technologies Q3 2025 revenue beats forecast

Agilent Technologies reported strong Q3 2025 results, with revenue reaching $1.74 billion, surpassing forecasts by $70 million, while EPS of $1.37 met expectations. The company achieved robust 6.1% core revenue growth, driven by strong demand in pharma and chemical/advanced materials, leading to a raised full-year revenue guidance of $6.91-$6.93 billion. However, operating margins were below expectations, impacted by higher tariff costs ($70 million for the second half of FY25), increased variable pay, and commercial investments, though management remains confident in fully mitigating tariff effects by FY2026 through its 'Ignite' operating model and strategic actions.

Analysis

Agilent Technologies (A) reported a robust third quarter, characterized by significant top-line outperformance offset by near-term margin pressures. Revenue of $1.74 billion surpassed consensus by $70 million, driven by strong core growth of 6.1% and leading to a substantial $150 million increase in the full-year revenue guidance midpoint to $6.92 billion. This strength was broad-based, with the key Pharma and Chemical & Advanced Materials end-markets growing 9% and 10% respectively, supported by successful new product launches and an instrument book-to-bill ratio exceeding one for six consecutive quarters. However, this top-line success did not fully translate to the bottom line, as operating margins of 25.1% fell below expectations. Management attributed this to three factors: higher-than-expected tariff costs now estimated at $70 million for the second half of the year, increased variable compensation tied to performance, and deliberate commercial investments to capture market momentum. While full-year EPS guidance remained flat at the midpoint, the company projects a significant sequential operating margin improvement of approximately 230 basis points in Q4 and expressed confidence in fully mitigating tariff impacts by fiscal 2026 through its 'Ignite' efficiency program.

Key Decisions for Investors

• Investors should weigh the strong top-line momentum, evidenced by the 6.1% core growth and raised revenue guidance, against the near-term margin headwinds from tariffs and strategic investments.
• It is critical to monitor for the projected 230 basis point sequential operating margin improvement in Q4, as achieving this would validate management's assertion that the current margin pressures are temporary.
• Consider the company's aggressive share buyback program and consistent dividend history as indicators of shareholder return, but factor in the risk that sustained tariff costs could impact future capital allocation.
• Look for continued strength in the Pharma and Chemicals end-markets and track the performance of new product platforms, as these are the primary drivers of the current growth acceleration and a key component of the bullish thesis for FY2026.